血栓激素G20210A和因子V莱登变异与先天性心脏病中的血栓事件无关:一项观察性试验
Feria A Ladha1, Christina VanderPluym2, Enrique Mondragon-Estrada3,4
1Department of Pediatrics Boston Children's Hospital Boston MA.
Journal of the American Heart Association
|March 4, 2026
概括
常见的血栓性变体,如前血G20210A和V因子莱登,与先天性心脏病 (CHD) 中的血栓性事件无关. 这表明不建议在心血管疾病患者中进行这些变异的常规基因查.
科学领域:
- 心血管遗传学 心血管遗传学
- 血栓形成的研究研究
- 儿童心脏病学 儿童心脏病学
背景情况:
- 患有先天性心脏病 (CHD) 的人患血栓事件的风险更高,包括急性缺血性中风.
- 常见的血栓友爱变体,如前列血G20210A和VLeiden因子对心脏病患者的这种风险的贡献尚不清楚.
研究的目的:
- 调查前列血G20210A和因子V莱登变体之间的关联,以及心脏病患者队列中血栓事件的发生.
主要方法:
- 利用了来自儿科心脏基因组学联盟的外体序列和电子病历数据.
- 根据原血G20210A和V因子莱登基因型,心室生理学和抗血栓治疗分层参与者.
- 使用国际疾病分类 (ICD) 或Phecodes识别的血栓事件.
主要成果:
- 与一般人群相比,心血管疾病队列表现出异构原蛋白G20210A和因子V莱登变异的发病率较低.
- 在患有或没有发生血栓事件的参与者之间,没有观察到变异患病率的显著差异.
- 单心室性心脏病与较高的血栓形成频率 (35%) 与双心室性心脏病 (16%),无论变体的流行率相关.
结论:
- 在这个多中心心血管疾病队列中,前素G20210A和因子V莱登变异与血栓结局没有显著的关联.
- 这些发现支持目前的建议,反对在CHD中针对这些特定的血栓友变体进行例行查.
- 较低的观察变异频率表明潜在的生存偏差,需要更大的综合临床基因组研究来精细化心脏病中血栓风险分层.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Venous Thrombosis I: Introduction
834
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
834
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
470
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
470
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


